Exercise on GLP-1s: what matters most

GLP-1 medications are approved as adjuncts to lifestyle change, not replacements for it. Below is what the trial data actually show, where the evidence runs out, and how to keep moving while your body adjusts.

The STEP 1 trial, one of the major studies for semaglutide, enrolled participants who received lifestyle counseling alongside the medication. Participants on semaglutide reported improved physical functioning scores compared to those on placebo, a meaningful finding even if an indirect one. But the trials did not test exercise as a variable. Physical activity was a background recommendation in STEP 1, not a controlled intervention. The trials did not compare exercise types, test specific training protocols, or measure outcomes like lean mass retention or athletic performance. Researchers were studying the medication; exercise was part of the lifestyle backdrop, not the experiment. This is an important limitation throughout. The trial data support exercise as part of the overall treatment approach, but they cannot tell you whether to prioritize cardio over strength training, how many days per week to work out, or what intensity is best. Those questions remain genuinely open.

What the trials did capture, in DEXA substudies, is that weight loss on these medications includes a meaningful share of lean mass. In STEP 1, roughly 39% of total weight lost was lean mass. In SURMOUNT-1, the figure ranged from 25 to 33% depending on tirzepatide dose. GLP-1 medications reduce caloric intake by an estimated 30 to 40%, and at that level of deficit, the body draws from both fat stores and lean tissue.

That ratio is not fixed. In the broader weight-loss literature, deliberate optimization through resistance training and adequate protein shifts the balance so that 85 to 90% of weight lost comes from fat. Those studies were not conducted in GLP-1 users, but the underlying physiology is the same. This is the core reason exercise warrants specific attention on these medications: it is a lever that may meaningfully change the composition of your weight loss, not just the pace.

GLP-1 medications work in part by reducing appetite. Many people eat significantly less than before starting treatment, especially in the early weeks, and less food means less available fuel. That can show up as lower workout intensity, slower recovery, or reduced motivation to exercise at all. The relationship between reduced caloric intake and exercise capacity in GLP-1 users specifically has not been directly studied. What follows draws on general sports nutrition and physiology principles, not GLP-1-specific research. With that caveat stated: fatigue during exercise on a caloric deficit may reflect underfueling, not unfitness. That distinction matters because the appropriate response to underfueling is different from the appropriate response to being out of shape. Pushing harder through fuel-related fatigue can backfire; adjusting intake or timing may help more. This is also where protein becomes especially relevant. When overall calories drop, adequate protein helps protect muscle tissue, which the next section addresses directly.

Resistance training has the strongest general evidence for preserving lean muscle mass during weight loss. This matters on GLP-1 medications because the weight loss these drugs produce includes both fat and muscle, a pattern common to most caloric deficits. Lifting weights, bodyweight exercises, and resistance bands are the most studied tools for limiting muscle loss during weight reduction. Aerobic exercise supports cardiovascular health, mood, and energy regulation. Obesity medicine guidelines recommend it as part of treatment, and there is no reason that changes when someone is on a GLP-1 medication. Combined approaches are what most clinical guidelines recommend. Neither modality has been proven superior specifically in GLP-1 users, because that comparison has not been studied in this population. At this stage of the evidence, consistency and sustainability matter more than optimization. The best exercise plan is one you can actually do.

For a concrete starting point, the WHO recommends 150 to 300 minutes per week of moderate-intensity aerobic activity plus muscle-strengthening activities on two or more days. These are general population guidelines, not GLP-1-specific, but they provide a floor. On the resistance side, the exercise science literature supports three to four sessions per week emphasizing compound movements (squats, rows, presses) with progressive overload. Beginners or those returning to training should start with two to three full-body sessions focused on learning mechanics before increasing volume.

Protein intake alongside resistance training is the other half of the equation. General recommendations for people in a caloric deficit range from 1.2 to 1.6 grams per kilogram of body weight per day; for actively training patients, 1.4 to 1.6 grams per kilogram is more commonly cited. These are sports nutrition figures, not GLP-1-specific, and individual targets depend on kidney function, overall diet, and how much food you can actually get down. A registered dietitian can help translate that range into a workable plan.

One additional finding: visceral fat shows a dose-dependent response to exercise, meaning more activity produces more visceral fat loss even when total weight loss is held constant. Caloric restriction alone appears to have diminishing returns for visceral fat beyond a certain threshold. This matters because exercise may be producing metabolic benefits in GLP-1 users that the scale does not capture.

Dose escalation, the period when your clinician gradually increases your dose, is when gastrointestinal side effects are most common. The STEP 1 trial data and semaglutide prescribing information both document nausea, vomiting, and diarrhea as frequent early side effects. These symptoms have practical implications for exercise. Nausea may limit how hard you can push during a workout. Vomiting or diarrhea raises the risk of dehydration. Vigorous exercise while dehydrated, especially in heat, warrants real caution. The prescribing information does not warn against exercise during dose escalation. The concern is managing GI symptoms and staying hydrated, not avoiding movement altogether. Scaling back intensity during high-symptom periods is sensible; stopping exercise entirely is not required or recommended. Light walking, gentle stretching, or lower-intensity activity during rough patches is a practical middle ground. The goal is to stay in the habit of moving, even when the medication is making things harder.

Timing can help. GI side effects tend to peak in the first one to three days after injection and ease afterward. Scheduling harder sessions three to five days post-injection, when symptoms are typically lowest, is a practical strategy. Avoiding high-intensity exercise within four hours of injection is another common approach, based on clinical experience rather than trial data.

Morning workouts before eating can reduce GI discomfort for some patients. Because GLP-1 medications slow gastric emptying, food sits in the stomach longer than it otherwise would. Eating two to three hours before exercise allows partial digestion and reduces the likelihood of nausea during a workout. During escalation periods when solid food is poorly tolerated, liquid nutrition such as a protein shake may be better absorbed post-workout than a full meal.

GLP-1 medications can affect recovery in ways that go beyond appetite and GI symptoms.

Clinical trial data show that GLP-1 receptor agonists raise resting heart rate by one to four beats per minute. The increase is modest and has not been associated with adverse cardiovascular outcomes in trial populations. But for patients who use heart rate zones to guide training, even a small upward shift means pre-medication baselines may no longer be accurate. Recalibrating zones based on current resting heart rate gives a more useful picture of actual effort.

Sleep is less straightforward. In clinical trials, insomnia rates on semaglutide or tirzepatide were generally similar to placebo. Real-world reports paint a more complicated picture: difficulty falling asleep, early-morning waking, and daytime fatigue are commonly described during dose escalation. About 11% of Wegovy trial participants reported unusual tiredness. GI symptoms, particularly nausea and heartburn, can directly interfere with sleep quality when lying down after eating.

There is a positive finding in the other direction. Tirzepatide showed significant improvement in obstructive sleep apnea scores in the SURMOUNT-OSA trials. And emerging research suggests that GLP-1 receptor agonists influence circadian rhythms and sleep-wake organization through pathways beyond their primary metabolic effects, though the clinical implications of this are still being worked out.

Recovery matters, and sleep is a large part of recovery. Patients who notice changes in sleep quality or daytime energy should raise those changes with their care team rather than assuming they are unrelated or inevitable.

Your care team is the right place to work through the specifics of your situation. Useful topics to raise:

How to adjust exercise intensity if GI symptoms are affecting your workouts

Whether your protein and caloric intake is sufficient to support the exercise you're doing

Signs of dehydration to watch for, especially during escalation phases

Whether any underlying conditions, cardiovascular, musculoskeletal, or otherwise, warrant a modified exercise plan

How to track changes in strength or endurance as a signal of muscle preservation, not just what the scale says

A registered dietitian can also be a useful resource, particularly for questions about protein targets and fueling around workouts.

No published trial has tested a specific exercise protocol in GLP-1 users and measured outcomes like lean mass retention, long-term weight maintenance, or physical performance. How reduced caloric intake affects exercise capacity in this population is not answered by current trial data. Whether exercise requirements change after stopping GLP-1 medications is unknown, as is whether a particular exercise approach helps people maintain weight loss after discontinuing these drugs. Several trials examining exercise alongside GLP-1 medications are underway or in development. Recommendations may shift as those results become available.

Among the most notable is the FLEX Trial at the University of Exeter, which is testing progressive resistance exercise combined with tirzepatide in overweight and obese females over 20 weeks. It is designed to measure body composition outcomes directly, the kind of data this field has been missing.

Some early adjacent results are worth noting. A 2026 secondary analysis in Sports Medicine examined combined exercise and liraglutide versus either alone over 52 weeks. The combination group showed stair climb time improved by 8.6%, peak VO2 improved by 3.0 mL/min/kg fat-free mass, and relative muscle strength increased by 3.3% versus a 7.8% decline in the placebo group. These are functional outcomes that matter for daily life. An important caveat: those results come from liraglutide, an older GLP-1 receptor agonist with different dosing and efficacy than semaglutide or tirzepatide. Whether the same exercise-medication interaction holds for the newer agents is plausible but not established.